|
|
Article: Neurocrine Biosciences Announces Indiplon Modified Release Demonstrates Lack of Respiratory Side Effects.
- Article from:
- PR Newswire
- Article date:
- May 6, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Data Presented at the American Psychiatric Association (APA) Meeting
Neurocrine Biosciences, Inc. announced today results from two Phase I studies demonstrating that indiplon modified release does not effect respiratory functioning in healthy subjects or those with mild-to-moderate chronic obstructive pulmonary disease (COPD). These results were presented today at the 157th annual meeting of the American Psychiatric Association (APA) in New York City.
The first study presented today was conducted in 12 healthy male volunteers in a double-blind crossover design with indiplon modified release 30 mg, codeine sulfate 60 mg (as a positive control), or ...